Walden University NURS 6630
Midterm Exam Practice Test
Psychopharmacologic
Approaches to Treatment of
Psychopathology
### Instructions:
This practice test is designed to prepare students for the NURS 6630 Midterm Exam at Walden
University. The exam covers neurobiology, pharmacokinetics, pharmacodynamics, and
psychopharmacologic treatment of major psychiatric disorders. Select the best answer for each
question.
---
## Section 1: Neurobiology & Pharmacodynamics
**Question 1:**
During gene expression, what must occur prior to a gene being expressed?
,A) RNA must be converted to mRNA
B) Transcription factor must bind to the regulatory region within the cell's nucleus
C) The coding region must separate from the regulatory region
D) RNA polymerase must inhibit the process of changing RNA to mRNA
**Answer: B**
*Rationale: Transcription factors must bind to the regulatory region (promoter) within the cell's nucleus
to initiate gene expression. This binding allows RNA polymerase to transcribe the gene into mRNA,
which is then translated into protein. This is a foundational concept in pharmacogenomics and
understanding individual medication responses .*
---
**Question 2:**
Though medications have the ability to target neurotransmitter release into the synapse by the
presynaptic neuron, it is not always necessary. The PMHNP understands that this is because:
A) Neurotransmission that occurs via the axon allows for transport of a neurotransmitter
B) Active transport is a different type of energy that allows the transport of certain neurotransmitters
C) Neurotransmitters can spread by diffusion
D) The postsynaptic neuron can release the neurotransmitter
**Answer: C**
*Rationale: Neurotransmitters can spread by diffusion across the synaptic cleft, allowing them to reach
receptors without requiring active reuptake or release mechanisms. This explains why medications that
target specific release mechanisms may not always be necessary for therapeutic effect .*
, ---
**Question 3:**
Why is the cytochrome P450 enzyme system of significance to the PMHNP?
A) The kidneys play a role with excretion of the medication, and if a patient has kidney damage, the dose
must be increased to be effective
B) The bioavailability of the medication after it passes through the stomach and liver can be altered
C) The medication's chemical composition changes when it comes in contact with the acid in the
stomach
D) The CYP enzyme system is a steady and predictable process that prescribers must understand to treat
conditions effectively
**Answer: B**
*Rationale: The cytochrome P450 enzyme system, primarily located in the liver, is responsible for
metabolizing many psychotropic medications. Genetic variations in CYP enzymes can significantly alter
drug bioavailability, affecting medication efficacy and toxicity risk. Understanding this system is essential
for safe prescribing and predicting drug interactions .*
---
**Question 4:**
As it relates to G-protein linked receptors, what does the PMHNP understand about medications that
are used in practice?
A) Most medications that act on G-protein linked receptors have antagonistic traits
B) The majority of medications used in practice are full agonists and are used to stimulate the body's
natural neurotransmitters
C) Most medications act as partial agonists because they allow the body to use only what is needed
Midterm Exam Practice Test
Psychopharmacologic
Approaches to Treatment of
Psychopathology
### Instructions:
This practice test is designed to prepare students for the NURS 6630 Midterm Exam at Walden
University. The exam covers neurobiology, pharmacokinetics, pharmacodynamics, and
psychopharmacologic treatment of major psychiatric disorders. Select the best answer for each
question.
---
## Section 1: Neurobiology & Pharmacodynamics
**Question 1:**
During gene expression, what must occur prior to a gene being expressed?
,A) RNA must be converted to mRNA
B) Transcription factor must bind to the regulatory region within the cell's nucleus
C) The coding region must separate from the regulatory region
D) RNA polymerase must inhibit the process of changing RNA to mRNA
**Answer: B**
*Rationale: Transcription factors must bind to the regulatory region (promoter) within the cell's nucleus
to initiate gene expression. This binding allows RNA polymerase to transcribe the gene into mRNA,
which is then translated into protein. This is a foundational concept in pharmacogenomics and
understanding individual medication responses .*
---
**Question 2:**
Though medications have the ability to target neurotransmitter release into the synapse by the
presynaptic neuron, it is not always necessary. The PMHNP understands that this is because:
A) Neurotransmission that occurs via the axon allows for transport of a neurotransmitter
B) Active transport is a different type of energy that allows the transport of certain neurotransmitters
C) Neurotransmitters can spread by diffusion
D) The postsynaptic neuron can release the neurotransmitter
**Answer: C**
*Rationale: Neurotransmitters can spread by diffusion across the synaptic cleft, allowing them to reach
receptors without requiring active reuptake or release mechanisms. This explains why medications that
target specific release mechanisms may not always be necessary for therapeutic effect .*
, ---
**Question 3:**
Why is the cytochrome P450 enzyme system of significance to the PMHNP?
A) The kidneys play a role with excretion of the medication, and if a patient has kidney damage, the dose
must be increased to be effective
B) The bioavailability of the medication after it passes through the stomach and liver can be altered
C) The medication's chemical composition changes when it comes in contact with the acid in the
stomach
D) The CYP enzyme system is a steady and predictable process that prescribers must understand to treat
conditions effectively
**Answer: B**
*Rationale: The cytochrome P450 enzyme system, primarily located in the liver, is responsible for
metabolizing many psychotropic medications. Genetic variations in CYP enzymes can significantly alter
drug bioavailability, affecting medication efficacy and toxicity risk. Understanding this system is essential
for safe prescribing and predicting drug interactions .*
---
**Question 4:**
As it relates to G-protein linked receptors, what does the PMHNP understand about medications that
are used in practice?
A) Most medications that act on G-protein linked receptors have antagonistic traits
B) The majority of medications used in practice are full agonists and are used to stimulate the body's
natural neurotransmitters
C) Most medications act as partial agonists because they allow the body to use only what is needed
